Illumina(US:ILMN) Prnewswire·2026-01-13 14:00Core Insights - Illumina, Inc. announced preliminary financial results for Q4 and fiscal year 2025 ahead of the J.P. Morgan Healthcare Conference [1] Preliminary Fourth Quarter 2025 Results - Revenue for Q4 2025 is approximately $1.155 billion, representing a 5% increase from Q4 2024 (4% increase on a constant currency basis) [7] - Ex-China revenue for Q4 2025 is approximately $1.100 billion, up 7% from Q4 2024 [7] - GAAP diluted EPS is projected to be between $2.14 and $2.17, while non-GAAP diluted EPS is expected to be between $1.27 and $1.30 [7] Preliminary Fiscal Year 2025 Results - Total revenue for fiscal year 2025 is approximately $4.34 billion, flat compared to 2024 (constant currency basis) [7] - Ex-China revenue for fiscal year 2025 is approximately $4.10 billion, up 2% from 2024 [7] - GAAP diluted EPS for the fiscal year is projected to be between $5.42 and $5.45, while non-GAAP diluted EPS is expected to be between $4.76 and $4.79 [7] Non-GAAP Financial Measures - The company reports non-GAAP results to provide a clearer view of operating performance, excluding certain charges such as amortization of acquired intangible assets and other adjustments [3][4] - Non-GAAP diluted EPS is a key metric used by the board of directors to assess management performance and compensation [3][14] Forward-Looking Guidance - The company provides forward-looking guidance on a non-GAAP basis, including revenue growth rates, but cannot reconcile these to GAAP measures due to uncertainties [5][6] About Illumina - Illumina focuses on improving human health through genomic technologies, serving various markets including life sciences, oncology, and agriculture [9]